clinical trial · NCT04436029
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Multiple MyelomaDescartes 11
brief summary
To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-11 in patients with high-risk myeloma who have residual disease following induction therapy.
started
Feb 24, 2021
primary completion
Feb 18, 2022
completion
Apr 9, 2022
last updated
Dec 3, 2024
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol